🇺🇸 FDA
Patent

US 11851449

Heterocyclic amide compounds having an RORvt inhibitory action

granted A61PA61P1/04A61P17/06

Quick answer

US patent 11851449 (Heterocyclic amide compounds having an RORvt inhibitory action) held by Takeda Pharmaceutical Company Limited expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61P, A61P1/04, A61P17/06, A61P19/02, A61P25/00